A. Halland

DSM-III-R classification of psychiatric symptoms in systemic lupus erythematosus.

R. Emsley, R. Hewlett, J. Maritz, 1996, Psychosomatics.

SAT0103 Lithe: Tocilizumab (TCZ) Inhibits Radiographic Progression and Improves Physical Function in Patients (PTS) With Rheumatoid Arthritis (RA) at 5 Years With Maintenance of Clinical Efficacy Over Time

J. Kremer, R. Burgos-Vargas, R. Fleischmann, 2013 .

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

Ricardo Blanco, J. Kremer, R. Burgos-Vargas, 2011, Arthritis and rheumatism.

Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results

J. Kremer, R. Burgos-Vargas, R. Fleischmann, 2013, The Journal of Rheumatology.

Musculoskeletal manifestations in hyperlipidaemia: a controlled study.

K. Steyn, P. Klemp, A. Halland, 1993, Annals of the rheumatic diseases.

Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.

J. Kremer, R. Burgos-Vargas, R. Fleischmann, 2016, Clinical and experimental rheumatology.

Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results

J. Kremer, R. Burgos-Vargas, R. Fleischmann, 2013, The Journal of Rheumatology.